stockrow
Saturday 7 November 2026
Export BBLG’s income statement to Excel — free account
Bone Biologics Corp.
BBLG Healthcare Biotechnology
- EPS
- +55.3%
- Free cash flow
- +9.99%
Quarter to September 2026, against a year earlier
0.32
0.00
0.00%
Follow BBLG
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | 0.0 pt | ||||||
| EBT | (26) | (7) | (4) | (3) | (2) | (2) | (1) | (9) | (4) | (3) | (3) | (21.0%) | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (26) | 0 | (4) | (3) | (2) | (2) | (1) | (9) | (4) | (3) | (3) | (21.0%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (17.25) | (4.50) | (528.93) | (676.95) | (903.35) | (511.06) | (187.16) | (204.02) | (28.97) | (2.65) | (1.40) | (18.8%) | ||||||
| Cash flow | (4.87) | (2.14) | (488.68) | (637.49) | (213.45) | (383.94) | (451.51) | (217.67) | (16.30) | (2.29) | (0.69) | (8.0%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (4.87) | (2.14) | (488.68) | (637.49) | (213.45) | (383.94) | (451.51) | (217.67) | (16.30) | (2.29) | (0.69) | (8.0%) | ||||||
| Book value | (5.56) | (5.39) | (1,023.60) | (2,326.98) | (6,846.15) | 2,054.84 | 752.82 | 66.21 | 13.77 | 4.58 | 1.59 | n/m | ||||||
| Shares, m | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | (2.7%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (7) | (3) | (4) | (3) | 0 | (1) | (4) | (10) | (4) | (3) | (3) | (10.5%) | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | (7) | (3) | (4) | (3) | 0 | (1) | (4) | (10) | (4) | (3) | (3) | (10.5%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | (1) | 0 | (9) | (1) | (14) | 7 | 6 | 3 | 3 | 5 | 6 | n/m | |||||
| Net debt | 8 | 8 | 8 | 11 | 12 | (7) | (8) | (3) | (3) | (5) | (6) | n/m | ||||||
| Shareholders’ equity | (8) | (8) | (9) | (12) | (14) | 7 | 6 | 3 | 3 | 5 | 6 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (3,457.87) | (2,011.58) | (508.72) | (639.25) | (11,848.70) | (48.04) | (19.57) | (146.30) | (192.78) | (64.39) | (44.46) | +3,393.5 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1,662.67) | (4,680.12) | 0.00 | (4,680.1) pt | ||||||
| ROE | 308.82 | 84.15 | 52.14 | 33.47 | 14.28 | 45.26 | (23.71) | (202.15) | (229.26) | (70.17) | (47.49) | (379.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 2 | 2 | 2 | 2 | 2 | 2 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
Bone Biologics Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LABT Lakewood-Amedex Biotherapeutics Inc. | $1.3M | — (loss-making) | — | — | n/m | −420.66% (below 0%: shrinking) | — | 0.00% | Compare |
| PTIX Atrinsic Inc. | $1.3M | 0.2× | — | +34.31% (above 0%: growing) | n/m | +46.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | $1.3M | — (loss-making) | — | −32.27% (below 0%: shrinking) | +96.36% (above 0%: growing) | −0.17% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARTL Artelo Biosciences, Inc. | $1.2M | — (loss-making) | — | — | n/m | −879.18% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MTNB Matinas Biopharma Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | +9.15% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | — | 0.00% | |
| VBIO Valion Bio, Inc. | $1.1M | — (loss-making) | — (loss-making) | +15.87% (above 0%: growing) | n/m | −189.01% (below 0%: shrinking) | (99.32%) | 0.00% | Compare |
| BPTH Bio-Path Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +98.68% (above 0%: growing) | 0.00% | 0.00% | Compare |
| JAGX Jaguar Animal Health, Inc. | $950.0K | — (loss-making) | — (loss-making) | −58.88% (below 0%: shrinking) | n/m | +13.83% (above 0%: growing) | 15.84% | (620.16%) | Compare |
| Median of peers | $1.2M | — | — | 0.00% | — | +4.49% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 28 August 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 426.27k | 430.79k | 0.02 |
| 2024 | 384.90k | 405.71k | 0.08 |
| 2023 | 376.60k | 332.97k | 0.37 |
Ownership
Directors and executive officers, together
5.00%
Intracoastal Capital LLC
9.90%
Armistice Capital, LLC
9.90%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement